{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975961",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975961_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"acebutolol\" outputclass=\"int-drug\">acebutolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  acebutolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acebutolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975962",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975962_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  aceclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975963",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975963_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"alcohol\" outputclass=\"int-drug\">alcohol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  alcohol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975964",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975964_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"alfuzosin\" outputclass=\"int-drug\">alfuzosin</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  alfuzosin  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975964_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"alfuzosin\" outputclass=\"int-drug\">alfuzosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  alfuzosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfuzosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975965",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975965_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  aliskiren  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975965_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975965_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">Irbesartan</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid <ph otherprops=\"aliskiren\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/aliskiren.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1252\">aliskiren</xref></ph> in selected patients</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Irbesartan   increases   the risk of renal impairment when given with   aliskiren .  Manufacturer advises use with caution or avoid  aliskiren  in selected patients .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975966",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975966_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  alprostadil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975967",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975967_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"amantadine\" outputclass=\"int-drug\">amantadine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  amantadine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amantadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975968",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975968_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975969",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975969_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  amitriptyline  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975970",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975970_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"amlodipine\" outputclass=\"int-drug\">amlodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  amlodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amlodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975971",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975971_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  apomorphine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975972",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975972_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"apraclonidine\" outputclass=\"int-drug\">apraclonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  apraclonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apraclonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975973",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975973_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"aripiprazole\" outputclass=\"int-drug\">aripiprazole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  aripiprazole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aripiprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975974",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975974_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  asenapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asenapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975975",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975975_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"atenolol\" outputclass=\"int-drug\">atenolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  atenolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atenolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975976",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975976_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"avanafil\" outputclass=\"int-drug\">avanafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  avanafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Avanafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975977",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975977_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  baclofen  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baclofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975978",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975978_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">bemiparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  bemiparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bemiparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975979",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975979_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  bendroflumethiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975980",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975980_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"benperidol\" outputclass=\"int-drug\">benperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  benperidol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975981",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975981_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"betaxolol\" outputclass=\"int-drug\">betaxolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  betaxolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betaxolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975982",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975982_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"bisoprolol\" outputclass=\"int-drug\">bisoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  bisoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bisoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975983",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975983_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  bortezomib  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975984",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975984_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"brimonidine\" outputclass=\"int-drug\">brimonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  brimonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brimonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975985",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975985_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"bromocriptine\" outputclass=\"int-drug\">bromocriptine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  bromocriptine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromocriptine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975986",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975986_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  bumetanide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975987",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975987_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"cabergoline\" outputclass=\"int-drug\">cabergoline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  cabergoline  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabergoline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975988",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975988_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  canagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975989",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975989_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  captopril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975989_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  captopril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975989_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975990",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975990_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  cariprazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cariprazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975991",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975991_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"carvedilol\" outputclass=\"int-drug\">carvedilol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  carvedilol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carvedilol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975992",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975992_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  celecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975993",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975993_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"celiprolol\" outputclass=\"int-drug\">celiprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  celiprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celiprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975994",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975994_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  chlorothiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975995",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975995_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  chlorpromazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975996",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975996_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  chlortalidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975997",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975997_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975998",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975998_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  clomipramine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975999",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857975999_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  clonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976000",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976000_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  clozapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976001",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976001_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">dalteparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  dalteparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976002",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976002_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  dapagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976003",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976003_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  darbepoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976004",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976004_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  desflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976005",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976005_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  dexketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976006",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976006_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"diazoxide\" outputclass=\"int-drug\">diazoxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  diazoxide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazoxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976007",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976007_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  diclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976008",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976008_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">diltiazem</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  diltiazem  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976009",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976009_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  dipyridamole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976010",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976010_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  dosulepin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976011",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976011_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"doxazosin\" outputclass=\"int-drug\">doxazosin</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  doxazosin  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976011_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"doxazosin\" outputclass=\"int-drug\">doxazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  doxazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976012",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976012_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  doxepin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976013",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976013_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  droperidol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976014",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976014_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976015",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976015_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  empagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976016",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976016_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  enalapril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976016_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  enalapril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976016_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976017",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976017_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">enoxaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  enoxaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976018",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976018_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  eplerenone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976018_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976019",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976019_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976020",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976020_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976021",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976021_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976022",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976022_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  epoprostenol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976023",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976023_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ertugliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976024",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976024_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"esketamine\" outputclass=\"int-drug\">esketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  esketamine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976025",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976025_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"esmolol\" outputclass=\"int-drug\">esmolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  esmolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esmolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976026",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976026_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  etodolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976027",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976027_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"etomidate\" outputclass=\"int-drug\">etomidate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  etomidate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etomidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976028",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976028_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  etoricoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976029",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976029_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"felodipine\" outputclass=\"int-drug\">felodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  felodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Felodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976030",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976030_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"flupentixol\" outputclass=\"int-drug\">flupentixol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  flupentixol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flupentixol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976031",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976031_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  flurbiprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976032",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976032_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"fosinopril\" outputclass=\"int-drug\">fosinopril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  fosinopril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976032_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"fosinopril\" outputclass=\"int-drug\">fosinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  fosinopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976033",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976033_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  furosemide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976034",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976034_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"glyceryl trinitrate\" outputclass=\"int-drug\">glyceryl trinitrate</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  glyceryl trinitrate  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976034_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"glyceryl trinitrate\" outputclass=\"int-drug\">glyceryl trinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  glyceryl trinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glyceryl trinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976035",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976035_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  guanfacine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanfacine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976036",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976036_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  haloperidol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976037",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976037_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"heparin\" outputclass=\"int-drug\">heparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  heparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976038",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976038_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"hydralazine\" outputclass=\"int-drug\">hydralazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  hydralazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydralazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976039",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976039_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  hydrochlorothiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976040",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976040_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  hydroflumethiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976041",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976041_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ibuprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976042",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976042_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  iloprost  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976043",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976043_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  imidapril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976043_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  imidapril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976043_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976044",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976044_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  imipramine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976045",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976045_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  indapamide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976046",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976046_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  indometacin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976047",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976047_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"indoramin\" outputclass=\"int-drug\">indoramin</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  indoramin  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976047_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"indoramin\" outputclass=\"int-drug\">indoramin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  indoramin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indoramin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976048",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976048_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  isocarboxazid  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976049",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976049_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  isoflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976050",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976050_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"isosorbide dinitrate\" outputclass=\"int-drug\">isosorbide dinitrate</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  isosorbide dinitrate  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976050_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"isosorbide dinitrate\" outputclass=\"int-drug\">isosorbide dinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  isosorbide dinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide dinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976051",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976051_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"isosorbide mononitrate\" outputclass=\"int-drug\">isosorbide mononitrate</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  isosorbide mononitrate  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976051_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"isosorbide mononitrate\" outputclass=\"int-drug\">isosorbide mononitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  isosorbide mononitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide mononitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976052",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976052_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ketamine\" outputclass=\"int-drug\">ketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ketamine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976053",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976053_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976054",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976054_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ketorolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976055",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976055_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"labetalol\" outputclass=\"int-drug\">labetalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  labetalol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Labetalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976056",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976056_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lacidipine\" outputclass=\"int-drug\">lacidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  lacidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lacidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976057",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976057_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lercanidipine\" outputclass=\"int-drug\">lercanidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  lercanidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lercanidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976058",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976058_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"levobunolol\" outputclass=\"int-drug\">levobunolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  levobunolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levobunolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976059",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976059_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"levodopa\" outputclass=\"int-drug\">levodopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  levodopa  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levodopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976060",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976060_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  levomepromazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976061",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976061_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  lisinopril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976061_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  lisinopril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976061_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976062",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976062_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">Irbesartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Irbesartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976063",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976063_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">lofepramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  lofepramine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofepramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976064",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976064_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  lofexidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976065",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976065_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  loxapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loxapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976066",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976066_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  lurasidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lurasidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976067",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976067_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  mefenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976068",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976068_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  meloxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976069",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976069_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"methoxyflurane\" outputclass=\"int-drug\">methoxyflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  methoxyflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methoxyflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976070",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976070_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"methyldopa\" outputclass=\"int-drug\">methyldopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  methyldopa  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methyldopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976071",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976071_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  metolazone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976072",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976072_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"metoprolol\" outputclass=\"int-drug\">metoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  metoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976073",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976073_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"minoxidil\" outputclass=\"int-drug\">minoxidil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  minoxidil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Minoxidil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976074",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976074_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"moxisylyte\" outputclass=\"int-drug\">moxisylyte</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  moxisylyte  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxisylyte</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976075",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976075_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  moxonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976076",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976076_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nabumetone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976077",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976077_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nadolol\" outputclass=\"int-drug\">nadolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nadolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nadolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976078",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976078_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  naproxen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976079",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976079_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nebivolol\" outputclass=\"int-drug\">nebivolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nebivolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nebivolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976080",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976080_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nicardipine\" outputclass=\"int-drug\">nicardipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nicardipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicardipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976081",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976081_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">nicorandil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nicorandil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976082",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976082_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nifedipine\" outputclass=\"int-drug\">nifedipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nifedipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nifedipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976083",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976083_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nimodipine\" outputclass=\"int-drug\">nimodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nimodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nimodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976084",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976084_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nitroprusside\" outputclass=\"int-drug\">nitroprusside</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nitroprusside  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitroprusside</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976085",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976085_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nitrous oxide\" outputclass=\"int-drug\">nitrous oxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nitrous oxide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrous oxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976086",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976086_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  nortriptyline  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976087",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976087_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  olanzapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976088",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976088_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  paliperidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976089",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976089_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  parecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976090",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976090_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  pericyazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pericyazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976091",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976091_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  perindopril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976091_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  perindopril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976091_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976092",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976092_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  phenazone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976093",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976093_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  phenelzine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976094",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976094_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  pimozide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976095",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976095_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"pindolol\" outputclass=\"int-drug\">pindolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  pindolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pindolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976096",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976096_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  piroxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976097",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976097_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976098",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976098_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976099",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976099_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976100",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976100_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"pramipexole\" outputclass=\"int-drug\">pramipexole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  pramipexole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pramipexole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976101",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976101_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"prazosin\" outputclass=\"int-drug\">prazosin</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  prazosin  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976101_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"prazosin\" outputclass=\"int-drug\">prazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  prazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976102",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976102_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  prochlorperazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prochlorperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976103",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976103_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  promazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976104",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976104_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"propofol\" outputclass=\"int-drug\">propofol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  propofol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propofol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976105",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976105_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"propranolol\" outputclass=\"int-drug\">propranolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  propranolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propranolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976106",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976106_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  quetiapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976107",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976107_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"quinagolide\" outputclass=\"int-drug\">quinagolide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  quinagolide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinagolide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976108",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976108_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  quinapril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976108_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  quinapril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976108_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976109",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976109_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ramipril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976109_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  ramipril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976109_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976110",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976110_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"riociguat\" outputclass=\"int-drug\">riociguat</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  riociguat  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Riociguat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976111",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976111_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  risperidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976112",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976112_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"ropinirole\" outputclass=\"int-drug\">ropinirole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  ropinirole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropinirole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976113",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976113_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"rotigotine\" outputclass=\"int-drug\">rotigotine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  rotigotine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotigotine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976114",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976114_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sacubitril\" outputclass=\"int-drug\">sacubitril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sacubitril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sacubitril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976115",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976115_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sapropterin\" outputclass=\"int-drug\">sapropterin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sapropterin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sapropterin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976116",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976116_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  selegiline  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976117",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976117_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sevoflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sevoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976118",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976118_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sildenafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976119",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976119_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sodium oxybate\" outputclass=\"int-drug\">sodium oxybate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sodium oxybate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium oxybate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976120",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976120_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sotalol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976121",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976121_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  spironolactone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976121_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976122",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976122_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sulindac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976123",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976123_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  sulpiride  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976124",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976124_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976125",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976125_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tadalafil\" outputclass=\"int-drug\">tadalafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tadalafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tadalafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976126",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976126_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tamsulosin\" outputclass=\"int-drug\">tamsulosin</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tamsulosin  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976126_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tamsulosin\" outputclass=\"int-drug\">tamsulosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  tamsulosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tamsulosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976127",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976127_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tenoxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976128",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976128_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"terazosin\" outputclass=\"int-drug\">terazosin</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  terazosin  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976128_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"terazosin\" outputclass=\"int-drug\">terazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  terazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976129",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976129_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  thiopental  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiopental</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976130",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976130_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tiaprofenic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976131",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976131_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"timolol\" outputclass=\"int-drug\">timolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  timolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Timolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976132",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976132_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">tinzaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tinzaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976133",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976133_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tizanidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976134",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976134_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tolfenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976135",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976135_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976136",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976136_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  torasemide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976137",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976137_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of first-dose hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  trandolapril  can increase the risk of first-dose hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976137_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  irbesartan  and  trandolapril  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976137_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  irbesartan  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976138",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976138_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  tranylcypromine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976139",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976139_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  treprostinil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976140",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976140_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976141",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976141_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  trifluoperazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trifluoperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976142",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976142_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  trimethoprim  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976143",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976143_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  trimipramine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976144",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976144_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  vardenafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976145",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976145_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"verapamil\" outputclass=\"int-drug\">verapamil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  verapamil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976146",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976146_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"vericiguat\" outputclass=\"int-drug\">vericiguat</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  vericiguat  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vericiguat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976147",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976147_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"vernakalant\" outputclass=\"int-drug\">vernakalant</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  vernakalant  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vernakalant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976148",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976148_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  xipamide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976149",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2#bnf_i1643857976149_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"irbesartan\" outputclass=\"int-heading-drug\">irbesartan</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  irbesartan  and  zuclopenthixol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Irbesartan  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/irbesartan-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Irbesartan </title>"
			},
			"rdfs:label": "irbesartan"
		}
	]
}